Skip to main content
. 2020 Feb 17;21(4):e49229. doi: 10.15252/embr.201949229

Figure 7. Targeting YTHDF1 in ISCs of established tumors leads to tumor shrinkage and prolonged survival.

Figure 7

  1. Workflow of tamoxifen (TAM)‐induced Ythdf1 deletion in AOM/DSS‐induced Lgr5‐creERT2:Ythdf1 fl/fl mice.
  2. Colons from mice in (A) treated with or without TAM on day 80 of AOM/DSS induction.
  3. Colon tumor number from mice treated with or without TAM on day 80 of AOM/DSS induction. Data are shown as mean ± SEM (7 mice for each group). ****P < 0.0001 (t‐test).
  4. Immunoblot analysis of 2 pairs of colon tumors from mice treated with or without TAM.
  5. Workflow of tamoxifen (TAM)‐induced Ythdf1 deletion in Apc min/+ mice.
  6. Kaplan–Meier survival plots for Apc min/+ ; Lgr5‐creERT2:Ythdf1 fl/fl mice (8 mice for each group) treated with or without TAM. Log‐rank (Mantel–Cox) test. **P < 0.01 (t‐test).
  7. A proposed model of amplified β‐catenin activity by m6A‐YTHDF1‐mediated translation.

Source data are available online for this figure.